The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?

ABSTRACT: Lung cancer is the leading cause of cancer-related death. Over the past 5-10 years lung cancer outcomes have significantly improved in part due to better treatment options including immunotherapy and molecularly targeted agents. Unfortunately, the majority of lung cancer patients do not enjoy durable responses to these new treatments. Seminal research demonstrated the importance of the gut microbiome in dictating responses to immunotherapy in melanoma patients. However, little is known regarding how other sites of microbiota in the human body affect tumorigenesis and treatment responses. The lungs were traditionally thought to be a sterile environment; however, recent research demonstrated that the lung contains its own dynamic microbiota that can influence disease and pathophysiology. Few

SUBMITTER: Weinberg F 

PROVIDER: S-EPMC7792810 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature